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The domiciliary immunisation service is centred on one immunisation nurse who has a commitment to the scheme and has the necessary attributes to be accepted both by the referring health visitor and the defaulting parents. An input is also required from health visitors and medical staff. The skills of the health visitor are used to identify suitable referrals and obtain parental consent. A doctor is needed in the home to assess medical fitness for immunisation and to give the injections, because all the referred children have a very poor clinic attendance record and the standard of child care is below the average for the district. Often an injection has to be deferred on medical grounds.
One particular nurse coordinates the domiciliary immunisation service, but the accompanying doctor is one of a group of interested community health doctors and community physicians. If the duty is shared in this way it cannot be considered to be a burden or a waste of professional time, and it is an effective way of obtaining first hand knowledge of the problems and health needs of the community.
I thank Dr Noel Preston, University of Manchester, for his help and encouragement in preparing this paper.
Introduction
Clinical trials have agreed widely that the long term prophylactic use of 13 adrenergic blocking drugs after myocardial infarction reduces mortality,'-5 but even though the evidence is probably accepted by most practising physicians, disagreement continues on how it should be translated into clinical practice. Is the reduction in mortality large enough to justify the cost in both human and economic terms? Is 1 blockade only worth while in certain categories of patient? How long is long term? To gain some insight into the effects of this recent research we carried out a simple survey among a sample of British cardiologists to assess their current clinical practice. In addition, we used this opportunity to investigate the feasibility of a clinical trial to establish the effect of withdrawing 13 blockade after one or two years' treatment after myocardial infarction (a "stopping trial").
Methods
A random sample of 100 cardiologists was drawn from a list of all British consultant cardiologists. Attempts were made to exclude those not in clinical practice. A questionnaire was sent to each member of the sample. Nonresponders were contacted again, first by letter and then by telephone. Incomplete or unclear forms were also corrected whenever possible after further contact by letter or telephone. Tables I-V show the questions asked. They were intended to be clear and simple and to relate to a limited number of important issues.
Results
Of the 100 doctors surveyed, six were found not to be practising cardiologists, three stated that they did not have postinfarction patients under their care, four refused to complete the form, and four did not respond in any way. There were thus 83 questionnaires for analysis from the 91 cardiologists supposedly eligible for the survey; 75 were complete.
Tables I-V summarise the responses to the questions. *"Younger patients who may be at increased risk," and "Policy (3) together with patients without angina but with a positive post myocardial infarction exercise test." Table IV summarises the proportion of patients treated with 1i blockers after myocardial infarction by the cardiologists in our sample. The overall proportion seemed to lie in the interval 25 to 50%. (To be certain of this we would need to know how many patients each cardiologist treated.) Interestingly, seven respondents reckoned to treat three quarters or more of their patients with f blockers. These seven all belonged to the group who treated prophylactically all patients except those with contraindications to f blockade.
About one third of the sample expressed interest in taking part in a stopping trial (table V); they estimated that they would contribute, in total, over 2500 patients a year. 
Discussion
The original list of consultant cardiologists from which the sample was drawn consisted of physicians from teaching and nonteaching hospitals. The size of our sample (about a quarter of the consultant cardiologists in the United Kingdom) and the high response to our survey ensured that it adequately represented the views of the British cardiological profession. Our results suggest that the evidence from clinical trials in favour of oral (3 blockade after myocardial infarction has been generally accepted, not only in theory but also in hospital practice. Is this evidence corroborated by an increase in prescriptions for ( blockers after discharge? Reliable figures are difficult to obtain. Such information, however, as can be gleaned from marketing surveys does not suggest an increasing tendency to prescribe ( blockers for ischaemic heart disease by general practitioners over the past few years (Intercontinental Medical Statistics Ltd, Medical Data Index, . This is also hinted at by Hampton.6 If this is true, there would seem to be a discrepancy between the intention of cardiologists and the practice of general practitioners. Cardiologists' practice could well differ from their own perception of it as reflected in our survey. Alternatively the explanation of the apparent discrepancy might lie with the cardiologists not controlling long term after care. These possibilities deserve further study.
The difference of opinions expressed about the duration of prophylaxis (table III) of treatment, and followed up for a further two years, it would seem reasonable to try to detect a 20% difference in mortality-similar to the confirmed benefit of i blockade. The practolol and timolol trials and the 3 blocker heart attack (BHAT) trial with propranolol suggest that this would represent a change in one to three year mortality from 6% to 4-8%. 
